EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Beta Bionics, Inc. Common Stock (BBNX) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Beta Bionics, Inc. Common Stock $5.04, price $22.19, upside -77.3%, quality 28 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US08659B1026

BB Beta Bionics, Inc. Common Stock logo Thin data Sep 24, 2026

Beta Bionics, Inc. Common Stock

BBNX · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $5.04 · Strongly overvalued (−77%)
!Quality 28/100
!Expensive Growth (revenue 3y +724.3 %/yr)
!Loss-making · -61.3% net margin (TTM)
!negative free cash flow
!Trails peers (1/9)
!Narrow moat 10/100
!Evidence only low, so the estimate is less certain
Watch Beta Bionics, Inc. Common Stock for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$31.99 $8.86 Fair Value $5.04 Jan 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

20‑month range $8.86 – $31.99 · fair‑value band $3.33 – $6.30 · the $22.19 price screens above the $5.04 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Beta Bionics, Inc. Common Stock in your weekly email

Every Wednesday you see whether Beta Bionics, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.

Show more

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.

Stock analysis

Beta Bionics, Inc. Common Stock (BBNX) currently trades at $22.19, while our model-based Fair Value estimate is $5.04, implying the stock looks roughly 340.3% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 92/100, which puts the evidence level at low.

Scenario range: $3.33 (bear) to $6.30 (bull), the price of $22.19 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Beta Bionics, Inc. Common Stock reported revenue of $100M in FY2025 versus $179K in FY2022, a compound +724.3%/yr. Reported net income was −$73.2M in FY2025.

Key figures

Market cap $988M · P/S ratio 6.26 · EPS (TTM) $−1.60 · Net margin −73.0% · Return on equity −26.2% · Return on assets (EBIT) −67.5% · Operating margin −79.9% · Revenue (TTM) $119M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 31% below its 52-week high and 150% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −77%, BBNX screens richer than that median.

Fair Value models

Bear $3.33 Fair Value $5.04 Bull $6.30
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $3.20 $4.28 $6.39 51
All 1 models by family
Asset-Based
NCAV (Graham) $3.20 $4.28 $6.39 51

Open the full fair value analysis →

Notify me when BBNX reaches fair value

Put BBNX on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 28/100

Of which business quality 32 · Market factors (momentum, volatility) 43

Profitability 9
Margins and returns on capital today
Quality Growth 71
Are margins and returns improving?
Cashflow 4
Earnings quality: real cash, not paper profit
Fin. Strength 83
Balance sheet, leverage, solvency risk
Investment 27
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 72
Price trend over the last 3–12 months (market factor)
52W Momentum 44
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+53.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+724.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−36,784.4% (2022) → −71.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

BBNX screens 340% overvalued. Compare with Abbott Laboratories, →

Compare Beta Bionics, Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 358 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −78% · Bottom 25%
Profitability
Return on assets −17% · Bottom 25%
Net margin (TTM) −61% · Bottom 25%
Operating margin (TTM) −80% · Bottom 25%
Growth and dividend
Revenue growth 38% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 3.53× · Priciest 25%
P/S (TTM) 8.54× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 4
FUTURE (revenue growth)100 · sector 31
PAST (return on equity)0 · sector 7
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 38

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $103.69 $74.79 −28%
Stryker Corporation SYK $275.09 $302.60 +10%
Medtronic plc MDT $90.77 $65.57 −28%
Boston Scientific Corporation BSX $44.92 $49.41 +10%
Edwards Lifesciences Corporation EW $88.78 $82.04 −8%
Siemens Healthineers AG SHL €37.43 €35.22 −6%
DexCom, Inc DXCM $89.53 $98.48 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Beta Bionics, Inc. Common Stock · Fair Value
$5.04 −340%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Beta Bionics, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/BBNX

Frequently asked questions

Is Beta Bionics, Inc. Common Stock (BBNX) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $5.04 versus a price of $22.19, about −77% upside (overvalued).
What is the fair value of BBNX?
Our model-based fair value for Beta Bionics, Inc. Common Stock is $5.04 (as of Sep 24, 2026), built from audited fundamentals. The current price: $22.19.
What is the quality score of BBNX?
Beta Bionics, Inc. Common Stock has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Beta Bionics, Inc. Common Stock (BBNX)?
Our model-based price target is the fair value of $5.04 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $3.33, optimistic scenario $6.30. It is a calculation from audited fundamentals, not an analyst target.
What is the Beta Bionics, Inc. Common Stock stock forecast for 2026?
Our models put fair value at $5.04, about −77% upside versus a price of $22.19 (overvalued). Cautious scenario $3.33, optimistic scenario $6.30. The calculation is refreshed regularly with new filings.
What is the revenue of Beta Bionics, Inc. Common Stock (BBNX)?
Beta Bionics, Inc. Common Stock reported trailing-twelve-month revenue of about $110M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Beta Bionics, Inc. Common Stock (BBNX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beta Bionics, Inc. Common Stock it is $5.04 per share (as of Sep 24, 2026), against a price of $22.19. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Beta Bionics, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Sep 24, 2026, BBNX trades above its calculated fair value: price $22.19, fair value $5.04, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BBNX?
No. The price is what the market pays today ($22.19); the fair value is what the company's own numbers justify ($5.04). For Beta Bionics, Inc. Common Stock the two are $17.15 per share apart. That gap is exactly why we show both numbers side by side.
How much is Beta Bionics, Inc. Common Stock worth?
The market values Beta Bionics, Inc. Common Stock at about $988M (market capitalisation, as of Sep 24, 2026). Per share that is $22.19; our models calculate a fair value of $5.04 per share.
What do the bullish and bearish scenarios say about BBNX?
Our models span a range for Beta Bionics, Inc. Common Stock: cautious scenario $3.33, base $5.04, optimistic $6.30 per share (as of Sep 24, 2026, price $22.19). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Beta Bionics, Inc. Common Stock (BBNX)?
Balance-sheet figures for Beta Bionics, Inc. Common Stock (as of Sep 24, 2026): return on equity −26.2%. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is BBNX from its 52-week high?
Beta Bionics, Inc. Common Stock trades at $22.19, about 31% below its 52-week high of $31.99 and 150% above the low of $8.86 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $5.04 is for.
Which stocks are comparable to Beta Bionics, Inc. Common Stock?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Beta Bionics, Inc. Common Stock stock attractive at the current price?
The data as of Sep 24, 2026: price $22.19, calculated fair value $5.04 (−77%), Quality Score 28/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BBNX calculated?
We run Beta Bionics, Inc. Common Stock through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $5.04, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Beta Bionics, Inc. Common Stock itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Beta Bionics, Inc. Common Stock (BBNX)?
The closing price on Sep 23, 2026 was $22.19. Our model-based fair value is $5.04, about −77% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Beta Bionics, Inc. Common Stock right now?
The price sits above even our optimistic bull case ($6.30). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($3.33 to $6.30) leaves room in how you read the outcome.

Key figures of Beta Bionics, Inc. Common Stock

How large is the market capitalisation of Beta Bionics, Inc. Common Stock (BBNX)?
The market capitalisation of Beta Bionics, Inc. Common Stock is $988M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Beta Bionics, Inc. Common Stock (BBNX)?
The price-to-sales ratio of Beta Bionics, Inc. Common Stock is 6.26 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Beta Bionics, Inc. Common Stock (BBNX)?
Earnings per share at Beta Bionics, Inc. Common Stock are $−1.60. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Beta Bionics, Inc. Common Stock (BBNX)?
The net margin of Beta Bionics, Inc. Common Stock is −73.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Beta Bionics, Inc. Common Stock (BBNX)?
The return on equity (ROE) of Beta Bionics, Inc. Common Stock is −26.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Beta Bionics, Inc. Common Stock (BBNX)?
On an EBIT basis the return on assets of Beta Bionics, Inc. Common Stock is −67.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Beta Bionics, Inc. Common Stock (BBNX)?
The operating margin of Beta Bionics, Inc. Common Stock is −79.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Beta Bionics, Inc. Common Stock (BBNX)?
Revenue at Beta Bionics, Inc. Common Stock is growing +37.8% versus a year earlier (3y avg +724%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Beta Bionics, Inc. Common Stock (BBNX) generate?
The free cash flow of Beta Bionics, Inc. Common Stock is −$56.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Beta Bionics, Inc. Common Stock (BBNX) hold?
Beta Bionics, Inc. Common Stock holds more cash than debt, $24.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Beta Bionics, Inc. Common Stock in the live analysis

One click puts Beta Bionics, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.